Evaluation of Multiple-Flows Exhaled Nitric Oxide and Its Clinical Significance in Severe Asthmatic Patients Treated with Biologics: A Prospective Real-Life Study

References

• Chung KF, Dixey P, Abubakar-Waziri H, Bhavsar P, Patel PH, Guo S, Ji Y. Characteristics, phenotypes, mechanisms and management of severe asthma. Chin Med J (Engl). 2022 May 20;135(10):1141-1155. doi:10.1097/CM9.0000000000001990.PMID: 35633594; PMCID: PMC9337252.
   Google Scholar
• McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019 Feb 15;199(4):433- 445. doi:10.1164/rccm.201810-1944CI.PMID: 30525902; PMCID: PMC6835092.
   Google Scholar
• Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. Clin Exp Allergy. 2022 May;52(5):616-627. doi:10.1111/cea.14112.Epub 2022 Mar 9. PMID: 35174566; PMCID: PMC9311192.
   Google Scholar
• Emma R, Morjaria JB, Fuochi V, Polosa R, Caruso M. Mepolizumab in the management of severe eosinophilic asthma in adults:current evidence and practical experience. Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808490. doi:10.1177/1753466618808490.PMID: 30354852; PMCID: PMC6204623.
   Google Scholar
• Jin HJ. Biological treatments for severe asthma. Yeungnam Univ J Med. 2020 Oct;37(4):262-268. doi:10.12701/yujm.2020.00647.Epub 2020 Sep 11. PMID: 32911591; PMCID: PMC7606967.
   Google Scholar
• Karrasch S., Linde K., Rücker G., Sommer H., Karsch-Völk M., Kleijnen J., Jörres R.A., Schneider A. Accuracy of FENO for Diagnosing Asthma: A Systematic Review. Thorax. 2017;72:109–116. doi:10.1136/thoraxjnl-2016-208704.
   Google Scholar
• Loewenthal L, Menzies-Gow A. FeNO in Asthma. Semin Respir Crit Care Med. 2022 Oct;43(5):635-645. doi:10.1055/s-0042-1743290.Epub 2022 Mar 4. PMID: 35253144.
   Google Scholar
• Ragnoli B, Radaeli A, Pochetti P, Kette S, Morjaria J, Malerba M. Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases. Ther Adv Chronic Dis. 2023 Aug 1;14:20406223231190480. doi:10.1177/20406223231190480.PMID: 37538344; PMCID: PMC10395178.
   Google Scholar
• Pianigiani T, Alderighi L, Meocci M, Messina M, Perea B, Luzzi S, Bergantini L, D'Alessandro M, Refini RM, Bargagli E, Cameli P. Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review. Antioxidants (Basel). 2023 Feb 7;12(2):400. doi:10.3390/antiox12020400.PMID: 36829959; PMCID: PMC9952501.
   Google Scholar
• Grob NM, Dweik RA. Exhaled nitric oxide in asthma. From diagnosis, to monitoring, to screening: are we there yet? Chest. 2008 Apr;133(4):837-9. doi:10.1378/chest.07-2743.PMID: 18398112.
   Google Scholar
• Li YH, Yu CJ, Qian XY, Song PP, Gao X. The correlation between FeNO and nNO in allergic rhinitis and bronchial asthma. Medicine (Baltimore). 2021 Oct 1;100(39):e27314. doi:10.1097/MD.0000000000027314.PMID: 34596130; PMCID: PMC8483846.
   Google Scholar
• Maniscalco M, Calabrese C, D'Amato M, Guida P, Molino A, Aliani M, De Tullio R, Foschino Barbaro M, Ricciardolo FLM, Carpagnano GE. Association between exhaled nitric oxide and nasal polyposis in severe asthma. Respir Med. 2019 Jun;152:20-24. doi:10.1016/j.rmed.2019.04.017.Epub 2019 Apr 25. PMID: 31128605.
   Google Scholar
• Horváth I, Barnes PJ, Loukides S, Sterk PJ, Högman M, Olin AC, Amann A, Antus B, Baraldi E, Bikov A, Boots AW, Bos LD, Brinkman P, Bucca C, Carpagnano GE, Corradi M, Cristescu S, de Jongste JC, Dinh-Xuan AT, Dompeling E, Fens N, Fowler S, Hohlfeld JM, Holz O, Jöbsis Q, Van De Kant K, Knobel HH, Kostikas K, Lehtimäki L, Lundberg J, Montuschi P, Van Muylem A, Pennazza G, Reinhold P, Ricciardolo FLM, Rosias P, Santonico M, van der Schee MP, van Schooten FJ, Spanevello A, Tonia T, Vink TJ. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017 Apr 26;49(4):1600965. doi:10.1183/13993003.00965-2016.PMID: 28446552.
   Google Scholar
• Chládková J, Senkerík M, Havlínová Z, Krcmová I, Chládek J. Alveolar concentration and bronchial flux of nitric oxide: two linear modeling methods evaluated in children and adolescents with allergic rhinitis and atopic asthma. Pediatr Pulmonol. 2012 Nov;47(11):1070-9. doi:10.1002/ppul.22550.Epub 2012 Apr 13. PMID: 22504930.
   Google Scholar
• Linn WS, Rappaport EB, Eckel SP, Berhane KT, Zhang Y, Salam MT, Bastain TM, Gilliland FD. Multiple-flow exhaled nitric oxide, allergy, and asthma in a population of older children. Pediatr Pulmonol. 2013 Sep;48(9):885-96. doi:10.1002/ppul.22708.Epub 2013 May 17. PMID: 23687084; PMCID: PMC3748140.
   Google Scholar
• Pavord I, Gardiner F, Heaney LG, Domingo C, Price RG, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Front Immunol. 2023 Apr 12;14:1150162. doi:10.3389/fimmu.2023.1150162.PMID: 37122713; PMCID: PMC10131245.
   Google Scholar
• Sposato B, Scalese M, Milanese M, et al. Factors reducing omalizumab response in severe asthma. European Journal of Internal Medicine. 2018;52:78-85. doi:10.1016/j.ejim.2018.01.026.
   Google Scholar
• Sposato B, Bianchi F, Ricci A, Scalese M. Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics. JPM. 2023;13(6):1020. doi:10.3390/jpm13061020.
   Google Scholar
• Rojo-Tolosa S, González-Gutiérrez MV, Sánchez-Martínez JA, et al. Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study. Pharmaceutics. 2023;15(2):523. doi:10.3390/pharmaceutics15020523.
   Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long- term therapy. Journal of Allergy and Clinical Immunology. 2017;140(1):162-169.e2. doi:10.1016/j.jaci.2016.08.054.
   Google Scholar
• McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. The Lancet Respiratory Medicine. 2021;9(10):1174-1184. doi:10.1016/S2213-2600(21)00004-7.
   Google Scholar
• Campisi R, Crimi C, Nolasco S, et al. Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program. JAA. 2021;Volume 14:575-583. doi:10.2147/JAA.S312123.
   Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-2496. doi:10.1056/NEJMoa1804092.
   Google Scholar
• Ramonell RP, Lee FEH, Levy JM, Kuruvilla M. Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma. Annals of Allergy, Asthma & Immunology. 2021;126(1):102-104. doi:10.1016/j.anai.2020.09.005.
   Google Scholar
• Kobayashi K, Nagase H, Sugimoto N, et al. Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma. Asia Pacific Allergy. 2021;11(3):e31. doi:10.5415/apallergy.2021.11.e31.
   Google Scholar
• Moran AM, Ramakrishnan S, Borg CA, et al. Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma. Am J Respir Crit Care Med. 2020;202(9):1314-1316. doi:10.1164/rccm.202003-0729LE.
   Google Scholar
• Huang YC, Leyko B, Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Annals of Allergy, Asthma & Immunology. 2005;95(5):443-451. doi:10.1016/S1081-1206(10)61170-2.
   Google Scholar
• Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A. RANTES in Exhaled Breath Condensate of Patients with Severe Persistent Allergic Asthma during Omalizumab Therapy. Int Arch Allergy Immunol. 2011;154(1):25-32. doi:10.1159/000319205.
   Google Scholar
• Muntean IA, Bocsan IC, Vesa S, et al. Could FeNO Predict AsthmaThe statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
   Google Scholar
• Chan EY, Ng DK, Chan C hong. Measuring FeNO in Asthma: Coexisting Allergic Rhinitis and Severity of Atopy as Confounding Factors. Am J Respir Crit Care Med. 2009;180(3):281-281. doi:10.1164/ajrccm.180.3.281.
   Google Scholar